Condition (MeSH)
Delayed Graft Function
ClinicalTrials.gov lists 82 trials for Delayed Graft Function or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
82 of the 82 trials are tagged with Delayed Graft Function itself; the rest are tagged with a narrower condition beneath it.
When did Delayed Graft Function trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Expanded access)
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 5 |
| 2024 | 3 |
| 2023 | 5 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 4 |
| 2018 | 2 |
| 2017 | 3 |
Showing 10 of 23 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 52 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Delayed Graft Function trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 6 |
| Phase 2 | 10 |
| Phase 2/3 | 2 |
| Phase 3 | 12 |
| Phase 4 | 15 |
| Not applicable | 15 |
| Observational | 16 |
| Expanded access | 1 |
How many Delayed Graft Function trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 6 |
| Active, not recruiting | 2 |
| Completed | 32 |
| Terminated | 11 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Delayed Graft Function trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Angion Biomedica Corp | 3 |
| Y's Therapeutics, Inc. | 3 |
| Alexion Pharmaceuticals, Inc. | 2 |
| Quark Pharmaceuticals | 2 |
| Apellis Pharmaceuticals, Inc. | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Delayed Graft Function? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| EVEROLIMUS | 3 |
| Eculizumab | 3 |
| ANG-3777 | 3 |
| YSPSL | 3 |
| EPOETIN ALFA | 2 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Belatacept LI (less intensive) | 4 |
| IR Tacrolimus | 4 |
| Furosemide-IR | 3 |
| Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)] | 3 |
| Mofetil Mycophenolate | 3 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Delayed Graft Function trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Grafts lost | 169 | 1 |
| Recipient Deaths | 166 | 1 |
| DGF in kidney recipients | 96 | 1 |
| Other | 35 | 1 |
| Renal insufficiency or increased creatinine level | 32 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Delayed Graft Function? (134)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Showing 5 of 134 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.